glp-1 and ssri Receptor Agonists in Mood Disorders: A Psychiatric Perspective GLP-1 Medications – Community Education

CrossRef Klothos impact on diabetic nephropathy and its emerging connection to diabetic retinopathy Anqi Tang, Yu Zhang, Ling Wu, Yong Lin, Lizeyu Lv, Liangbin Zhao, Bojun Xu, Youqun Huang, Mingquan Li Frontiers in Endocrinology.2023;[Epub] CrossRef Differences and Clinical Significance of Serum 25-Hydroxyvitamin D3 and Vasohibin-1 (VASH-1) Levels in Patients with Diabetic Nephropathy and Different Renal Injuries Hui Liu, Dongyan Wang, Jingnan Tang, Linlin Yu, Shanshan Su Diabetes, Metabolic Syndrome and Obesity.2023

Conclusion The discovery of GLP-1 agonists' potential in treating chronic kidney disease is an exciting development in medical research

Zavacki, A

Qualifying criteria include BMI greater than 27 with prediabetes or established cardiovascular disease, or BMI over 30 with uncontrolled hypertension, advanced kidney disease, or heart failure

GLP-1 drugs break this cycle by: Improving fat cell insulin sensitivity Reducing fat storage Enhancing energy utilization The result

But these medications interact with multiple organ systems, the pancreas, kidneys, thyroid, and liver chief among them